Novel anti-obesity quercetin-derived Q2 prevents metabolic disorders in rats fed with high-fat diet

• Published in: Vascular pharmacology 2018-04, Vol.103-105, p.58-58
• Main Authors: Rocca, C., Albano, L., Granieri, M.C., Amelio, D., Nettore, I.C., Macchia, P.E., Sinicropi, S., Ungaro, P., Angelone, T.
• Format: Article
• Language: English
• Subjects: Accumulation; Anthropometry; Bioavailability; Body weight; Cardiovascular diseases; Diabetes mellitus; Diet; Differentiation; Disorders; Dyslipidemia; Gene expression; Glucose; Glucose tolerance; Health risks; High fat diet; Hypertrophy; Liver; Metabolic disorders; Molecular chains; Morbidity; mRNA; Obesity; Polymerase chain reaction; Preadipocytes; Proteins; Quercetin; Rats; Risk analysis; Risk factors; Rodents; Steatosis; Weight reduction
• ISSN: 1537-1891; 1879-3649
• DOI: 10.1016/j.vph.2017.12.030

Objective: Obesity is often accompanied by an increased morbidity and mortality due to an increase of the cardiovascular disease risk factors, diabetes mellitus and dyslipidemia. Research is constantly working on protective molecules against obesity. In the present study, a novel Quercetin derivative Q2 was synthesized to overcome the poor bioavailability and low stability of Quercetin, a natural flavonoid with antioxidative and antiobesity properties. Methods: Rats were fed (12ws) with normodiet (fat: 6.2%), High Fat Diet (fat:60%), HFD + Q2 in water (500 nM). Metabolic and anthropometric parameters were measured. 3T3-L1 preadipocytes were incubated with Q2 (1-25μM) and the differentiation program was evaluated by lipid accumulation through ORO staining. Gene and protein expression levels were assessed by RT-PCR and Western blot analysis. Results: Compared to HFD, HFD + Q2 rats showed reduced body weight, abdominal obesity, dyslipidemia and improved glucose tolerance. This is associated to lower adipose and liver modifications compared to hypertrophy and steatosis observed in HFD. In 3T3-L1 cells, lipid accumulation was significantly impaired by treatment with Q2. Indeed, Q2 significantly decreased the expression of the main adipogenic markers, c/EBPα and PPARγ both at mRNA and protein level. Conclusions: Our results indicate that Q2 markedly decreases differentiation of 3T3-L1 preadipocytes and contributes to prevent metabolic disorders as well as adipose and liver alterations typical of severe obesity induced by a HFD.